SG11202103102WA - Adeno-associated virus compositions for targeted gene therapy - Google Patents

Adeno-associated virus compositions for targeted gene therapy

Info

Publication number
SG11202103102WA
SG11202103102WA SG11202103102WA SG11202103102WA SG11202103102WA SG 11202103102W A SG11202103102W A SG 11202103102WA SG 11202103102W A SG11202103102W A SG 11202103102WA SG 11202103102W A SG11202103102W A SG 11202103102WA SG 11202103102W A SG11202103102W A SG 11202103102WA
Authority
SG
Singapore
Prior art keywords
adeno
gene therapy
associated virus
targeted gene
virus compositions
Prior art date
Application number
SG11202103102WA
Inventor
Viviana Gradinaru
Nicholas C Flytzanis
Nicholas S Goeden
Original Assignee
California Inst Of Techn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Inst Of Techn filed Critical California Inst Of Techn
Publication of SG11202103102WA publication Critical patent/SG11202103102WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
SG11202103102WA 2018-09-26 2019-09-25 Adeno-associated virus compositions for targeted gene therapy SG11202103102WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862736904P 2018-09-26 2018-09-26
US201962832812P 2019-04-11 2019-04-11
PCT/US2019/052969 WO2020068990A1 (en) 2018-09-26 2019-09-25 Adeno-associated virus compositions for targeted gene therapy

Publications (1)

Publication Number Publication Date
SG11202103102WA true SG11202103102WA (en) 2021-04-29

Family

ID=69953332

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202103102WA SG11202103102WA (en) 2018-09-26 2019-09-25 Adeno-associated virus compositions for targeted gene therapy

Country Status (9)

Country Link
US (2) US11149256B2 (en)
EP (1) EP3856913A4 (en)
JP (1) JP2022502046A (en)
KR (1) KR20210084459A (en)
CN (1) CN113966399A (en)
AU (1) AU2019346447A1 (en)
CA (1) CA3114199A1 (en)
SG (1) SG11202103102WA (en)
WO (1) WO2020068990A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019040586A1 (en) * 2017-08-25 2019-02-28 Ovid Therapeutics Inc. Recombinant adeno-associated vectors
CA3105381A1 (en) 2018-07-11 2020-01-16 The Brigham And Women's Hospital, Inc. Methods and compositions for delivery of agents across the blood-brain barrier
WO2020068990A1 (en) 2018-09-26 2020-04-02 California Institute Of Technology Adeno-associated virus compositions for targeted gene therapy
AU2020214831A1 (en) * 2019-01-30 2021-08-12 The Broad Institute, Inc. Systems for evolved adeno-associated viruses (AAVs) for targeted delivery
WO2021141692A2 (en) 2019-11-22 2021-07-15 California Institute Of Technology Method for robust control of gene expression
TW202208397A (en) 2020-05-13 2022-03-01 美商航海家醫療公司 Redirection of tropism of aav capsids
WO2022040530A2 (en) * 2020-08-21 2022-02-24 Capsida, Inc. Virus compositions for treating mucopolysaccharidosis ii
US20220119475A1 (en) * 2020-09-14 2022-04-21 President And Fellows Of Harvard College Recombinant adeno associated virus encoding clarin-1 and uses thereof
CA3201533A1 (en) 2020-11-11 2022-05-19 European Molecular Biology Laboratory Modified viral particles for gene therapy
EP4294461A1 (en) * 2021-02-22 2023-12-27 Decibel Therapeutics, Inc. Methods and compositions for reducing nucleic acid vector-induced toxicity in the inner ear
WO2022221420A2 (en) 2021-04-13 2022-10-20 Capsida, Inc. Selected aav compositions having preferred brain enrichment
CA3217699A1 (en) * 2021-05-06 2022-11-10 Melissa J. SPENCER Novel aav serotypes derived from a library screen
US20230086710A1 (en) * 2021-09-14 2023-03-23 California Institute Of Technology Aav capsid variants
WO2023049710A1 (en) * 2021-09-21 2023-03-30 California Institute Of Technology Viral compositions for targeting the nervous system and the lung
WO2023091948A1 (en) * 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
US11732566B2 (en) 2021-11-22 2023-08-22 Saudi Arabian Oil Company Slickwater hydraulic fracturing with exothermic reactants
KR20240048599A (en) * 2022-10-06 2024-04-16 주식회사 글루진테라퓨틱스 Adeno-associated virus vector capable of lung bronchial-specific gene delivery
CN116693633B (en) * 2023-02-21 2023-12-22 广州派真生物技术有限公司 Adeno-associated virus mutant and application thereof
CN116790612B (en) * 2023-06-21 2024-02-02 江苏省人民医院（南京医科大学第一附属医院） Peroxisome germinal protein 3 for promoting myocardial regeneration and repair and application thereof

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919676A (en) 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
US6379943B1 (en) 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
US6228646B1 (en) 1996-03-07 2001-05-08 The Regents Of The University Of California Helper-free, totally defective adenovirus for gene therapy
EP1696036B1 (en) 1996-09-06 2010-04-21 The Trustees of The University of Pennsylvania Use of recombinant adeno-associated virus in the manufacture of a medicament for gene therapy via muscle cells
EP0950111A1 (en) 1996-09-06 1999-10-20 The Trustees Of The University Of Pennsylvania Methods using cre-lox for production of recombinant adeno-associated viruses
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
DE19933719A1 (en) 1999-07-19 2001-01-25 Medigene Ag Structural protein in adeno-associated virus with altered chromatographic properties, its production and use
US6429001B1 (en) 2000-01-26 2002-08-06 Chiron Corporation Recombinant AAV packaging systems
AU2001269723B9 (en) 2000-06-01 2006-11-16 University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
US6410271B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Generation of highly diverse library of expression vectors via homologous recombination in yeast
US7749492B2 (en) * 2001-01-05 2010-07-06 Nationwide Children's Hospital, Inc. AAV vectors and methods
US20070172460A1 (en) 2003-03-19 2007-07-26 Jurgen Kleinschmidt Random peptide library displayed on aav vectors
WO2005017101A2 (en) 2003-05-19 2005-02-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH Avian adenoassociated virus (aaav) and uses thereof
US9233131B2 (en) 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
PT3211085T (en) 2003-09-30 2021-06-17 Univ Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
WO2006099615A2 (en) 2005-03-16 2006-09-21 The Johns Hopkins University Adenoviral fiber exchange shuttle system
US20090093403A1 (en) 2007-03-01 2009-04-09 Feng Zhang Systems, methods and compositions for optical stimulation of target cells
EP2007795B1 (en) * 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid proteins
DK3023500T3 (en) 2006-06-21 2020-04-20 Uniqure Ip Bv Insect cells for the production of AAV vectors
AU2008218109A1 (en) 2007-02-23 2008-08-28 University Of Florida Research Foundation, Inc. Compositions and methods for treating glycogen storage diseases
CA3002933A1 (en) 2007-07-14 2009-01-22 Beverly L. Davidson Methods and compositions for treating brain diseases
US9018138B2 (en) 2007-08-16 2015-04-28 The Johns Hopkins University Compositions and methods for generating and screening adenoviral libraries
WO2009108274A2 (en) * 2008-02-26 2009-09-03 The University Of North Carolina At Chapel Hill Methods and compositions for adeno-associated virus (aav) with hi loop mutations
RU2010147661A (en) 2008-04-23 2012-05-27 Дзе Борд Оф Трастиз Оф Дзе Лелэнд Стэнфорд Джуниор Юниверсити (Us) SYSTEMS, METHODS AND COMPOSITIONS FOR THE OPTICAL STIMULATION OF TARGET CELLS
US20110223635A1 (en) 2008-08-11 2011-09-15 Karl Deisseroth Method and Composition for Controlling Gene Expression
CN106011073A (en) 2010-03-17 2016-10-12 小利兰·斯坦福大学托管委员会 Light-sensitive ion-passing molecules
WO2011133890A1 (en) 2010-04-23 2011-10-27 University Of Massachusetts Cns targeting aav vectors and methods of use thereof
WO2012103343A1 (en) 2011-01-28 2012-08-02 The Board Of Trustees Of The Leland Stanford Junior University Functional targeted brain endoskeletonization
SG194583A1 (en) 2011-04-22 2013-12-30 Univ California Adeno-associated virus virions with variant capsid and methods of use thereof
US9169299B2 (en) 2011-08-24 2015-10-27 The Board Of Trustees Of The Leleand Stanford Junior University AAV capsid proteins for nucleic acid transfer
EP2791333B1 (en) 2011-12-16 2019-03-06 The Board of Trustees of the Leland Stanford Junior University Opsin polypeptides and methods of use thereof
ES2628006T3 (en) 2012-02-21 2017-08-01 Circuit Therapeutics, Inc. Compositions for the treatment of neurogenic disorders of the pelvic floor
WO2014052789A1 (en) 2012-09-28 2014-04-03 The University Of North Carolina At Chapel Hill Aav vectors targeted to oligodendrocytes
MX2015015560A (en) 2013-05-15 2016-06-17 Univ Minnesota Adeno-associated virus mediated gene transfer to the central nervous system.
EP3564379A1 (en) 2013-09-13 2019-11-06 California Institute of Technology Selective recovery
CN105530917B (en) 2013-09-19 2020-06-05 扬森疫苗与预防公司 Improved adenovirus formulations
US10794802B2 (en) 2013-09-20 2020-10-06 California Institute Of Technology Whole-body tissue stabilization and selective extractions via tissue-hydrogel hybrids for high resolution intact circuit mapping and phenotyping
CA2924478A1 (en) 2013-09-20 2015-03-26 California Institute Of Technology Methods for phenotyping of intact whole tissues
WO2015127128A2 (en) 2014-02-19 2015-08-27 University Of Massachusetts Recombinant aavs having useful transcytosis properties
US10746742B2 (en) 2014-04-25 2020-08-18 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
WO2015168666A2 (en) 2014-05-02 2015-11-05 Genzyme Corporation Aav vectors for retinal and cns gene therapy
CN107073051B (en) 2014-10-21 2021-08-24 马萨诸塞大学 Recombinant AAV variants and uses thereof
CN107532173A (en) 2014-11-21 2018-01-02 北卡罗来纳-查佩尔山大学 Target the AAV carriers of central nervous system
JP6836999B2 (en) 2015-03-24 2021-03-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ Adeno-associated virus mutants and how to use them
EP3831842A1 (en) 2015-09-28 2021-06-09 The University of North Carolina at Chapel Hill Methods and compositions for antibody-evading virus vectors
US20180230489A1 (en) 2015-10-28 2018-08-16 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
EP3368065A4 (en) 2015-10-29 2019-03-20 Voyager Therapeutics, Inc. Delivery of central nervous system targeting polynucleotides
AU2016366549B2 (en) 2015-12-11 2022-11-10 California Institute Of Technology Targeting peptides for directing adeno-associated viruses (AAVs)
FI3411484T3 (en) 2016-02-05 2023-11-15 Univ Emory Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid
AU2017219865B2 (en) 2016-02-16 2023-04-13 The Board Of Trustees Of The Leland Stanford Junior University Novel recombinant adeno-associated virus capsids resistant to pre-existing human neutralizing antibodies
WO2017192750A1 (en) 2016-05-04 2017-11-09 Oregon Health & Science University Recombinant adeno-associated viral vectors
ES2941502T3 (en) 2016-05-13 2023-05-23 4D Molecular Therapeutics Inc Variants of adeno-associated virus capsids and methods of using them
MA44546B1 (en) 2016-06-15 2021-03-31 Univ California Variant adeno-associated viruses and methods of use
JP7071332B2 (en) 2016-07-29 2022-05-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Adeno-associated virus virions with mutant capsids and how to use them
US20190192693A1 (en) 2016-09-02 2019-06-27 Spark Therapeutics, Inc. Methods and vectors for treating cns disorders
US11578340B2 (en) 2016-10-13 2023-02-14 University Of Massachusetts AAV capsid designs
MX2019005266A (en) 2016-11-04 2019-09-27 The Children´S Hospital Of Philadelphia Gene transfer compositions, methods and uses for treating neurodegenerative diseases.
US20230048025A1 (en) 2016-12-22 2023-02-16 Oregon Health & Science University Adeno associated viral vectors
BR112019016769A2 (en) 2017-02-15 2020-05-26 The University Of North Carolina At Chapel Hill METHODS AND COMPOSITIONS FOR GENETIC TRANSFER THROUGH VASCULATURE
US10550405B2 (en) * 2017-03-15 2020-02-04 The University Of North Carolina At Chapel Hill Rational polyploid adeno-associated virus vectors and methods of making and using the same
TWI808079B (en) 2017-04-03 2023-07-11 美商編碼製藥公司 Tissue selective transgene expression
US11603542B2 (en) * 2017-05-05 2023-03-14 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
WO2018222503A1 (en) 2017-05-31 2018-12-06 The Regents Of The University Of California Adeno-associated virus with variant capsid and methods of use thereof
CN110461368A (en) 2017-06-30 2019-11-15 加利福尼亚大学董事会 Adeno-associated virus virion and its application method with variant capsids
CA3071978A1 (en) 2017-08-03 2019-02-07 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
CN110709511A (en) 2017-08-28 2020-01-17 加利福尼亚大学董事会 Adeno-associated virus capsid variants and methods of use thereof
SG11202002276VA (en) 2017-09-20 2020-04-29 4D Molecular Therapeutics Inc Adeno-associated virus variant capsids and methods of use thereof
EP4272728A2 (en) 2017-11-27 2023-11-08 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and use for inhibiting angiogenesis
CN112004820B (en) 2018-03-30 2023-09-12 利兰斯坦福初级大学董事会 Novel recombinant adeno-associated virus capsids with enhanced human pancreatic tropism
AU2019258830A1 (en) 2018-04-27 2020-12-03 Universität Heidelberg Modified AAV capsid polypeptides for treatment of muscular diseases
US20210230632A1 (en) 2018-05-15 2021-07-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
WO2019222441A1 (en) 2018-05-16 2019-11-21 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
EP3793615A2 (en) 2018-05-16 2021-03-24 Voyager Therapeutics, Inc. Directed evolution of aav to improve tropism for cns
WO2020028751A2 (en) 2018-08-03 2020-02-06 Voyager Therapeutics, Inc. Aav variants with enhanced tropism
WO2020061079A1 (en) 2018-09-18 2020-03-26 California Institute Of Technology Engineered light-sensitive proteins
WO2020068990A1 (en) 2018-09-26 2020-04-02 California Institute Of Technology Adeno-associated virus compositions for targeted gene therapy
US20210371470A1 (en) 2018-10-12 2021-12-02 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
MX2021011701A (en) 2019-03-28 2021-12-10 Massachusetts Gen Hospital Engineered adeno-associated (aav) vectors for transgene expression.
TW202102526A (en) 2019-04-04 2021-01-16 美商銳進科斯生物股份有限公司 Recombinant adeno-associated viruses and uses thereof
US20220220502A1 (en) 2019-04-11 2022-07-14 California Institute Of Technology Virus compositions with enhanced specificity in the brain
BR112021020421A2 (en) 2019-04-12 2021-12-21 Encoded Therapeutics Inc Compositions and methods for administering therapeutic components
JP2022530457A (en) 2019-04-26 2022-06-29 サンガモ セラピューティクス， インコーポレイテッド Genetically engineered AAV
AU2020282352B2 (en) 2019-05-29 2023-05-18 Encoded Therapeutics, Inc. Compositions and methods for selective gene regulation

Also Published As

Publication number Publication date
CN113966399A (en) 2022-01-21
JP2022502046A (en) 2022-01-11
KR20210084459A (en) 2021-07-07
WO2020068990A1 (en) 2020-04-02
US20240101969A9 (en) 2024-03-28
US20220119775A1 (en) 2022-04-21
AU2019346447A1 (en) 2021-04-29
US20200165576A1 (en) 2020-05-28
EP3856913A1 (en) 2021-08-04
CA3114199A1 (en) 2020-04-02
US11149256B2 (en) 2021-10-19
EP3856913A4 (en) 2022-10-26

Similar Documents

Publication Publication Date Title
SG11202103102WA (en) Adeno-associated virus compositions for targeted gene therapy
GB2592822B (en) Therapeutic compositions
HK1257563A1 (en) Targeting peptides for directing adeno-associated viruses (aavs)
EP3645021A4 (en) Adeno-associated viral vectors for gene therapy
EP3784284C0 (en) Lipid-based formulations for the delivery of rna
IL266264A (en) Adeno-associated virus formulations
ZA201906613B (en) Pharmaceutical compositions for combination therapy
ZA201905510B (en) Pharmaceutical compositions for combination therapy
EP4125815A4 (en) Therapeutic compositions
IL279685A (en) Gene therapy
GB201820018D0 (en) Therapeutic hydrogel compositions
GB201518456D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
IL271154A (en) Compounds and compositions for inducing chondrogenesis
EP3500279A4 (en) Methods and compositions for treating canine conditions using recombinant self-complementary adeno-associated virus
GB201707212D0 (en) Gene therapy for ciliopathies
PT3823655T (en) Compositions for the treatment of vulvodynia
IL268708B (en) Pharmaceutical compositions for combination therapy
GB201905301D0 (en) Gene therapy
GB201820983D0 (en) Virus
GB201802326D0 (en) Gene therapy
EP3966323A4 (en) Targeted therapy
IL275613A (en) Gene therapy for eosinohilic disorders
GB201817470D0 (en) Gene therapy
EP3760209C0 (en) Ischemic-lesion-site-specific gene therapy
GB201820982D0 (en) Gene Therapy